BRAND_ANALYSIS #ILLUMINA HEALTH & PHARMA #14 OF 26 IN HEALTH & PHARMA ALIGNED

Illumina

· Public · Updated 22 Nov 2026 07:19 UTC
#395 of 1208 overall by tension · #14 of 26 in Health & Pharma
12 Aligned
The Balanced
Analysis

Illumina sequences the genome for clinics and researchers, and C=40 with B=52 reflects a company whose science matters enormously to a small world and very little to the public. A -28.43% stock drop over 30 days shows investors punishing the sector's uncertainty. At #395, the most important biotech tool in the room is also the most financially bruised.

IN THE NEWS (34 articles this week)
Introducing the CellularAI algorithm: Predicting single-cell responses to genetic perturbations - Illumina
Illumina announces layoffs at San Diego headquarters - San Diego Union-Tribune
Illumina to Cut 51 Jobs at San Diego Headquarters - GenomeWeb
Cultural Score
40 / 100
Business Score
52 / 100
TENSION▁▂▂▂▁▂▂▂▂▁▁▁▁▁
CULTURAL▄▄▄▄▄▄▄▄▃▃▄▃▃▃
BUSINESS▅▅▅▅▃▅▅▅▅▄▄▄▄▄
Loading...
Wikipedia Momentum 15/40
News Presence 26/35
Search InterestRedistributed to other dimensions
Stock Momentum 4/30
Market Position 16/25
Revenue Growth 15/25
Earnings Health 17/20
Price$192.82
30d Change-28.4%
Market Cap$29.2B
Profit Margin19.7%
Illumina's tension is 12. Commerce outpacing culture. sociologyofcapitalism.com/brand/illumina
SHARE ON X
EMBED
<iframe src="https://sociologyofcapitalism.com/embed/illumina.html" width="320" height="200" frameborder="0"></iframe>